Skye Bioscience, Inc. SKYE
NASDAQ · United States · Health Technology
$1.60-0.01 (-0.62%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Skye Bioscience Inc (SKYE) merges with Redx Pharma to create a fibrosis-focused powerhouse, offering shareholders a 5.4% stake and a contingent value right on Nimacimab monetization.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.